This site is for customers in Asia. Customers in China & other regions, please go to Global page.
HOME > Product search results > Code No. K0186-4 Anti-HLA-A2 (Human) mAb-FITC

Code No. K0186-4

Anti-HLA-A2 (Human) mAb-FITC

Availability (in Japan)

10 or more

(In Japan at 17:00,
Apr 12, 2021 in JST)


50 µg/100 µL

Clonality Monoclonal Clone BB7.2
Isotype (Immunized Animal) Mouse IgG2b
10 µg/mL (final concentration)  
Immunogen (Antigen) papain solubilized HLA-A2
Reactivity [Gene ID]


Storage buffer 500 µg/mL in PBS/1% BSA/0.1% ProClin150
Storage temp. 4°C Conjugate FITC Manufacturer MBL
Background Human leukocyte antigen-A2 (HLA-A2) is a class I molecule of the human major histocompatibility complex (MHC). It is a heterodimer composed of a 43 kDa a subunit that is non-covalently associated with the 12 kDa β2-microglobulin protein. HLA-A2, like other class I molecules, binds peptides from proteins degraded in the cytoplasm and plays a role in antigen presentation and interaction with CD8+ T cells. HLA-A2 is the most common HLA-A allele in the Caucasian and American Indian populations (50% and ~30%, respectively) and A2 restricted T cell epitopes have been studied widely.
Related products K0186-3 Anti-HLA-A2 (Human) mAb
K0186-5 Anti-HLA-A2 (Human) mAb-PE
K0208-3 Anti-HLA-A24 (Human) mAb
K0208-4 Anti-HLA-A24 (Human) mAb-FITC
K0208-5 Anti-HLA-A24 (Human) mAb-PE
K0208-A48 Anti-HLA-A24 (Human) mAb-Alexa Fluor® 488
K0208-A64 Anti-HLA-A24 (Human) mAb-Alexa Fluor® 647
K0209-3 Anti-HLA-A24 (Human) mAb
K0209-4 Anti-HLA-A24 (Human) mAb-FITC
K0209-5 Anti-HLA-A24 (Human) mAb-PE
K0126-3 Anti-HLA-E (Human) mAb
K0215-3 Anti-HLA-E (Human) mAb

Flow Cytometry

  1. Suzuki S et al. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cacer Sci. 102, 1622-9 (2011)(PMID:21668581)
  2. Kobayashi E et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med. 19, 1542-6 (2013)(PMID:24121927)
  3. Chang AY et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 127, 2705-2718 (2017)(PMID:28628042)
  4. Nishio-Nagai M et al. Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. Int J Oncol. 51, 1471-1481 (2017)(PMID:29048671)
Product category
Research area
Cell surface antigens

  • The availability is based on the information in Japan at 17:00, Apr 12, 2021 in JST.
  • The special price is shown in red color.
  • Please note that products cannot be ordered from this website. To purchase the items listed in this website, please contact us or local distributers.
  • Abbreviations for applications:
    WB: Western Blotting, IH: Immunohistochemistry, IC: Immunocytochemistry, IP: Immunoprecipitation
    FCM: Flow Cytometry, NT: Neutralization, IF: Immunofluorescence, RIP: RNP Immunoprecipitation
    ChIP: Chromatin Immunoprecipitation, CoIP: Co-Immunoprecipitation
  • For applications and reactivity:
    *: The use is reported in a research article (Not tested by MBL). Please check the data sheet for detailed information.
    **: The use is reported from the licenser (Under evaluation or not tested by MBL).
  • For storage temparature: RT: room temparature
  • Please note that products in this website might be changed or discontinued without notification in advance for quality improvement.